Clomipramine Plus Bupropion Co-Prescribing
Co-prescribing clomipramine (Anafranil) with bupropion is not listed as an absolute contraindication on drug labeling. (dailymed.nlm.nih.gov)
Combination therapy increases risk for adverse effects related to seizure threshold and exposure to CYP2D6-metabolized drugs, so dose-limiting caution and monitoring are required. (drugs.com)
Medication Selection Algorithm
- Tricyclic antidepressant therapy (including clomipramine) may be used when indicated, with caution for seizure risk. (dailymed.nlm.nih.gov)
- Bupropion may be used with caution in patients taking other drugs that can lower the seizure threshold. (dailymed.nlm.nih.gov)
- When both agents are used concurrently, initiation at lower doses and gradual titration are recommended for the concomitant CYP2D6-substrate drug strategy described in labeling-based interaction management. (drugs.com)
Key Evidence Supporting This Recommendation
- Clomipramine labeling advises caution in patients with a history of seizures or other predisposing factors, including concomitant use with other drugs that lower the seizure threshold. (dailymed.nlm.nih.gov)
- Bupropion labeling advises extreme caution when coadministered with other drugs that lower seizure threshold. (dailymed.nlm.nih.gov)
- Bupropion labeling includes a CYP2D6 interaction finding in which bupropion increased desipramine exposure ~2-fold to ~5-fold in a study of CYP2D6 extensive metabolizers, supporting the potential for increased TCA exposure when treated as CYP2D6-substrate strategy. (accessdata.fda.gov)
Monotherapy Versus Combination Therapy
- Monotherapy avoids additive seizure-threshold lowering from multiple antidepressants. (dailymed.nlm.nih.gov)
- Combination therapy may be considered when clinical targets are not achieved with monotherapy, but it requires caution due to seizure-threshold overlap and potential increased clomipramine exposure if CYP2D6-mediated metabolism is clinically relevant. (dailymed.nlm.nih.gov)
Important Clarifications and Nuances
- Clomipramine labeling identifies the need for caution with concomitant CNS-active drugs and for monitoring of TCA plasma levels when clomipramine is co-administered with strong CYP2D6 inhibitors. (dailymed.nlm.nih.gov)
- Bupropion is a CYP2D6 inhibitor, which can increase concentrations of CYP2D6 substrates; this supports added caution when coadministering with TCAs. (dailymed.nlm.nih.gov)
Treatment Initiation Thresholds
- Bupropion labeling advises caution in patients with conditions that increase seizure risk and advises extreme caution when coadministered with other drugs that lower seizure threshold. (dailymed.nlm.nih.gov)
- Clomipramine labeling advises caution in patients with a history of seizures and with concomitant use of other drugs that lower seizure threshold. (dailymed.nlm.nih.gov)
- Interaction-based management guidance for concomitant CYP450 2D6 substrates supports initiation at the lower end of the dose range and gradual titration when bupropion is coadministered with CYP2D6 substrates. (drugs.com)
Common Pitfalls to Avoid
- Avoid combining clomipramine and bupropion in patients with seizure history or other seizure-predisposing factors without heightened caution, because labeling identifies these risk scenarios for each drug. (dailymed.nlm.nih.gov)
- Avoid rapid dose escalation when both drugs are used together, because interaction management based on CYP2D6-substrate strategy recommends lower initial dosing and gradual titration. (drugs.com)
- Avoid under-monitoring for toxicity from increased exposure to a TCA when CYP2D6-mediated effects are possible, because clomipramine labeling describes desirability of monitoring TCA plasma levels with CYP2D6-inhibitor coadministration. (dailymed.nlm.nih.gov)
Targets or Goals of Therapy
- The therapy goal is maintenance of antidepressant efficacy while minimizing seizure risk and other clomipramine and bupropion adverse effects through dose conservatism and monitoring. (dailymed.nlm.nih.gov)
Practical Monitoring Considerations
- Seizure risk should be reassessed at initiation and during titration because both agents warn about seizure threshold risk with predisposing factors or concomitant seizure-threshold-lowering drugs. (dailymed.nlm.nih.gov)
- Monitoring for clomipramine-related toxicity should be performed when exposure may increase through CYP2D6 interaction considerations. (accessdata.fda.gov)
Bottom-Line Safety Statement
Clomipramine and bupropion can be prescribed together only with caution due to combined seizure-threshold risk and CYP2D6 interaction potential, with low-dose initiation and gradual titration and vigilant adverse-effect monitoring. (dailymed.nlm.nih.gov)